Complications from carcinoid syndrome: review of the current evidence

José Mauricio Mota, Luana Guimarães Sousa, Rachel P Riechelmann, José Mauricio Mota, Luana Guimarães Sousa, Rachel P Riechelmann

Abstract

Patients with well-differentiated neuroendocrine tumours may develop carcinoid syndrome (CS), which is characterised by flushing, abdominal cramps, diarrhoea, and bronchospasms. In this scenario, long-term secretion of vasoactive substances-serotonin, tachynins, and others, may induce fibrogenic responses in local or distant tissues, leading to complications such as carcinoid heart disease (CHD), mesenteric and/or retroperitoneal fibrosis. Rare cases of lung/pleural fibrosis and scleroderma have also been described. Despite it not being well described yet, current evidence suggests the pathogenesis of such fibrogenic complications relies on signalling through 5-HT2B and TGF-β1. Medical management is still very limited and lacks prospective and randomised studies for definitive recommendations. Surgical procedures remain the best definitive treatment option for CHD and abdominal fibrosis. Recently, cognitive impairment has also been described as a potential consequence of CS. This review critically discusses the literature concerning the epidemiology, pathogenesis, clinical features, diagnosis, and treatment options for CS-related long-term complications.

Keywords: carcinoid heart disease; carcinoid syndrome; complications; fibrosis.

Figures

Figure 1.. Fibrosis with mesenteric retraction in…
Figure 1.. Fibrosis with mesenteric retraction in a patient with CS.
Figure 2.. Main complications from CS and…
Figure 2.. Main complications from CS and proposed pathogenesis.

References

    1. Yao JC, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. doi: 10.1200/JCO.2007.15.4377.
    1. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–10.
    1. Møller JE, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005–15. doi: 10.1056/NEJMoa021451.
    1. Modlin IM, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51. doi: 10.1053/j.gastro.2005.03.038.
    1. Vinik AI, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am. 1989;18(4):865–96. Available: .
    1. Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci. 1994;733:464–70. doi: 10.1111/j.1749-6632.1994.tb17296.x. Available: .
    1. Bernheim AM, Connolly HM, Pellikka PA. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol. 2007;99(2):292–4. doi: 10.1016/j.amjcard.2006.07.092.
    1. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18(2):133–41.
    1. Dobson R, et al. The clinical presentation and management of carcinoid heart disease. Int J Cardiol. 2014;173(1):29–32. doi: 10.1016/j.ijcard.2014.02.037.
    1. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22(4):517–30.
    1. Pellikka P a, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87(4):1188–96. doi: 10.1161/01.CIR.87.4.1188.
    1. Denney WD, et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol. 1998;32(4):1017–22. doi: 10.1016/S0735-1097(98)00354-4.
    1. Jacobsen MB, et al. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J. 1995;16(2):263–8.
    1. Bhattacharyya S, et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107(8):1221–6. doi: 10.1016/j.amjcard.2010.12.025.
    1. Simula DV, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77(2):139–47. doi: 10.1016/S0025-6196(11)62328-8.
    1. Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid Heart Disease: From Pathophysiology to Treatment - Something in the Way It Moves. Neuroendocrinology. 2015;101(4):263–73. doi: 10.1159/000381930.
    1. Musunuru S, et al. A mouse model of carcinoid syndrome and heart disease. J Surg Res. 2005;126(1):102–5. doi: 10.1016/j.jss.2005.01.003.
    1. Zuetenhorst JM, et al. Carcinoid heart disease. Cancer. 2003;97(7):1609–1615. doi: 10.1002/cncr.11226.
    1. Robiolio PA, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92(4):790–5. doi: 10.1161/01.CIR.92.4.790.
    1. Bhattacharyya S, et al. Drug-induced fibrotic valvular heart disease. Lancet. 2009;374(9689):577–585. doi: 10.1016/S0140-6736(09)60252-X.
    1. Rajamannan NM, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis. 2001;10(6):827–31.
    1. Gustafsson BI, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation. 2005;111(12):1517–22. doi: 10.1161/01.CIR.0000159356.42064.48.
    1. Hafizi S, et al. Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. J Heart Valve Dis. 2000;9(3):454–8.
    1. Hutcheson JD, et al. Serotonin receptors and heart valve disease-It was meant 2B. Pharmacol Ther. 2011;132(2):146–157. doi: 10.1016/j.pharmthera.2011.03.008.
    1. Nebigil CG, et al. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation. 2003;107(25):3223–9. doi: 10.1161/01.CIR.0000074224.57016.01.
    1. Nebigil C, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A. 2000;97(17):9508–13. doi: 10.1073/pnas.97.17.9508.
    1. Jian B, et al. Serotonin Mechanisms in Heart Valve Disease I. Am J Pathol American Society for Investigative Pathology. 2002;161(6):2111–21. doi: 10.1016/S0002-9440(10)64489-6.
    1. Waltenberger J, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993;142(1):71–8.
    1. Bergestuen DS, et al. Activin A in carcinoid heart disease: A possible role in diagnosis and pathogenesis. Neuroendocrinology. 2010;92(3):168–177. doi: 10.1159/000318014. [pii]
    1. Oates JA, et al. Release of a kinin peptide in the carcinoid syndrome. Lancet. 1964;1(17332):514–7. doi: 10.1016/S0140-6736(64)92907-1.
    1. Bergestuen DS, et al. Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer. 2010;10:6. doi: 10.1186/1471-2407-10-6.
    1. Patel C, et al. Carcinoid heart disease: Current understanding and future directions. Am Heart J. 2014;167(6):789–95. doi: 10.1016/j.ahj.2014.03.018.
    1. Gustafsson BI, et al. Carcinoid heart disease. Int J Cardiol. 2008;129(3):318–24. doi: 10.1016/j.ijcard.2008.02.019.
    1. Bhattacharyya S, et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101(3):378–81. doi: 10.1016/j.amjcard.2007.08.045.
    1. Chua Chiaco JMS, Parikh NI, Fergusson DJ. The jugular venous pressure revisited. Cleve Clin J Med. 2013;80(10):638–44. doi: 10.3949/ccjm.80a.13039.
    1. Bernheim AM, et al. Carcinoid heart disease. Prog Cardiovasc Dis. 2007;49(6):439–51. doi: 10.1016/j.pcad.2006.12.002.
    1. Bhattacharyya S, et al. Features of carcinoid heart disease identified by 2-and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3(1):103–11. doi: 10.1161/CIRCIMAGING.109.886846.
    1. Mansencal N, et al. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J. 2006;151(5):1129. doi: 10.1016/j.ahj.2006.02.019.
    1. Moerman VM, Dewilde D, Hermans K. Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance. Acta Cardiol. 2012;67(2):245–8. doi: 10.2143/AC.67.2.2154218.
    1. Franzen D, et al. Magnetic resonance imaging of carcinoid heart disease. Clin Cardiol. 2009;32(6):92–3. doi: 10.1002/clc.20260.
    1. Pape UF, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135–56. doi: 10.1159/000335629.
    1. Plöckinger U, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology. 2009;90(2):190–3. doi: 10.1159/000225947.
    1. Bhattacharyya S, et al. Circulating plasma and platelet 5-hydroxytryptamine in carcinoid heart disease: a pilot study. J Heart Valve Dis. 2013. 2013;22(3):400–7.
    1. Zuetenhorst JM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003;97(7):1609–15. doi: 10.1002/cncr.11226.
    1. Bhattacharyya S, et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102(7):938–42. doi: 10.1016/j.amjcard.2008.05.047.
    1. Zuetenhorst JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004;90(11):2073–9. doi: 10.1038/sj.bjc.6601816.
    1. Dobson R, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One. 2013;8(9):e73679. doi: 10.1371/journal.pone.0073679.
    1. Dobson R, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111(9):1703–9. doi: 10.1038/bjc.2014.468.
    1. Møller JE, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112(21):3320–7. doi: 10.1161/CIRCULATIONAHA.105.553750.
    1. Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol. 1989;63(5):347–52. doi: 10.1016/0002-9149(89)90344-5.
    1. Westberg G, et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88(6):865–72. doi: 10.1046/j.0007-1323.2001.01798.x.
    1. Mansencal N, et al. Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease. Am J Cardiol. 2010;105(4):527–31. doi: 10.1016/j.amjcard.2009.10.023.
    1. Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63. doi: 10.1200/JCO.2009.22.8510.
    1. Rinke A, et al. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long term survival. Neuroendocrinology. 2016. pp. 1–7.
    1. Pavel ME, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12. doi: 10.1016/S0140-6736(11)61742-X.
    1. Bernheim AM, et al. Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc. 2008;83(2):143–50. doi: 10.1016/S0025-6196(11)60834-3.
    1. Kulke MH, et al. Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) Eur J Cancer. 2015;51:S728. doi: 10.1016/S0959-8049(16)31951-7.
    1. Zacks J, et al. Telotristat etiprate appears to halt carcinoid heart disease. 13th Annu ENETS Conf. 2016. Abstract M8.
    1. Lafaras CT, et al. Evaluation of treatment with bosentan in patients with carcinoid heart disease: Single center study. Onkologie. 2010;33(6):300–4. doi: 10.1159/000313596.
    1. Janssen W, et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015. pp. 1–9.
    1. Fabre A, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J. 2008;32(2):426–36. doi: 10.1183/09031936.00126907.
    1. Edwards NC, et al. Effect of valvular surgery in carcinoid heart disease: an observational cohort study. J Clin Endocrinol Metab. 2016;101(1):183–90. doi: 10.1210/jc.2015-3295.
    1. Connolly HM, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25(2):410–6. doi: 10.1016/0735-1097(94)00374-Y.
    1. Robiolio PA, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995;75(7):485–8. doi: 10.1016/S0002-9149(99)80586-4.
    1. Connolly HM, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66(20):2189–96. doi: 10.1016/j.jacc.2015.09.014.
    1. Mokhles P, et al. Carcinoid heart disease: outcomes after surgical valve replacement. Eur J Cardiothorac Surg. 2012;41(6):1278–83. doi: 10.1093/ejcts/ezr227.
    1. Castillo JG, Silvay G, Solís J. Current concepts in diagnosis and perioperative management of carcinoid heart disease. Semin Cardiothorac Vasc Anesth. 2013;17(3):212–23. doi: 10.1177/1089253212465475.
    1. Propst JW, Siegel LC, Stover EP. Anesthetic considerations for valve replacement surgery in a patient with carcinoid syndrome. J Cardiothorac Vasc Anesth. 1994;8(2):209–12. doi: 10.1016/1053-0770(94)90065-5.
    1. Castillo JG, et al. Management of patients undergoing multivalvular surgery for carcinoid heart disease: The role of the anaesthetist. Br J Anaesth. 2008;101(5):618–26. doi: 10.1093/bja/aen237.
    1. Lillegard JB, et al. Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? J Am Coll Surg. 2011;213(1):130–6. doi: 10.1016/j.jamcollsurg.2011.03.029. discussion 136–8.
    1. Ridker PM, et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J. 1991;121(6 Pt 1):1835–8. doi: 10.1016/0002-8703(91)90045-J.
    1. Ohri SK, et al. Carcinoid heart disease: early failure of an allograft valve replacement. Ann Thorac Surg. 1994;58(4):1161–3. doi: 10.1016/0003-4975(94)90479-0.
    1. Thorburn CW, et al. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol. 1983;51(7):1128–32. 1983.
    1. Connolly HM, et al. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation. 2002;106(12 Suppl):I51–6.
    1. Carrilho-Ferreira P, et al. Carcinoid heart disease: outcome after balloon pulmonary valvuloplasty. Can J Cardiol. 2013;29(6):751.e7–9. doi: 10.1016/j.cjca.2012.09.015.
    1. Hargreaves AD, Pringle SD, Boon NA. Successful balloon dilatation of the pulmonary valve in carcinoid heart disease. Int J Cardiol. 1994;45(2):150–1. doi: 10.1016/0167-5273(94)90274-7.
    1. Mansencal N, et al. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease. Am J Cardiol. 2008;101(7):1035–8. doi: 10.1016/j.amjcard.2007.11.056.
    1. Hellman P, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26(8):991–7. doi: 10.1007/s00268-002-6630-z.
    1. Capurso G, et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99(11):1480–6. doi: 10.1002/bjs.8842.
    1. Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009;5(5):276–83. doi: 10.1038/nrendo.2009.51.
    1. Morgan JG, Marks C, Hearn D. Carcinoid tumors of the gastrointestinal tract. Ann Surg. 1974;180(5):720–7. doi: 10.1097/00000658-197411000-00003.
    1. Petrik PK. Fatal small intestinal infarction due to occlusion by mesenteric carcinoid tumor. Am J Forensic Med Pathol. 1989;10(2):146–8. doi: 10.1097/00000433-198906000-00011.
    1. Druce MR, et al. Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine (’carcinoid’) tumours of the small bowel. QJM. 2010;103(3):177–85. doi: 10.1093/qjmed/hcp191.
    1. Sakai D, et al. Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis. Pathol Int. 2000;50(5):404–11. doi: 10.1046/j.1440-1827.2000.01053.x.
    1. Gupta A, et al. Retroperitoneal fibrosis caused by carcinoid tumour. Q J Med. 1985;56(219):367–75.
    1. Biasco E, et al. Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen. Tumori. 2015;101(1):e24–8. doi: 10.5301/tj.5000259.
    1. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: An association with no explanation. Am J Gastroenterol. 2004;99(12):2466–78. doi: 10.1111/j.1572-0241.2004.40507.x. 2004.
    1. Zarafonetis CJ, Lorber SH, Hanson SM. Association of functioning carcinoid syndrome and scleroderma. I. Case report. Am J Med Sci. 236(1):1–14. 1958.
    1. Ratnavel RC, Burrows NP, Pye RJ. Scleroderma and the carcinoid syndrome. Clin Exp Dermatol. 1994;19(1):83–5. doi: 10.1111/j.1365-2230.1994.tb01126.x. Available: .
    1. Bell HK, et al. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152(1):71–5. doi: 10.1111/j.1365-2133.2004.06273.x.
    1. Kucuk O, et al. Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer. 1988;62(5):1026–9.
    1. Becher G, Leman J. Cutaneous scleroderma and malignant carcinoid syndrome. Clin Exp Dermatol. 2013;38(3):310–1. doi: 10.1111/ced.12046.
    1. Bivens CH, Marecek RL, Feldman JM. Peyronie’s disease–a presenting complaint of the carcinoid syndrome. N Engl J Med. 1973;289(16):844–5. doi: 10.1056/NEJM197310182891608.
    1. Moss SF, et al. Pleural involvement in the carcinoid syndrome. Q J Med. 1993;86(1):49–53. 1993.
    1. Tamagno G, et al. Lung fibrosis in carcinoid syndrome. Intern Med. 2007;46:425–6. doi: 10.2169/internalmedicine.46.6367.
    1. Miller RR, Müller NL. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol. 1995;19(6):653–8. doi: 10.1097/00000478-199506000-00005.
    1. Kahil M, Brown H, Fred HL. The carcinoid syndrome. Arch Intern Med. 1964;114:26–8. doi: 10.1001/archinte.1964.03860070072004.
    1. Moneret-Vautrin DA, Laxenaire MC. Anaphylactoid or carcinoid crisis? Br J Anaesth. 1993;71(4):609–10. doi: 10.1093/bja/71.4.609.
    1. Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159(1):358–67. doi: 10.1016/j.surg.2015.05.036.
    1. Massimino K, et al. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013;107(8):842–6. doi: 10.1002/jso.23323.
    1. Morrisroe K, et al. Carcinoid crisis induced by repeated abdominal examination. Intern Med J. 2012;42(3):342–4. doi: 10.1111/j.1445-5994.2012.02719.x.
    1. Kharrat H Al, Taubin H. Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol. 2003;36(1):87–8. doi: 10.1097/00004836-200301000-00031.
    1. Koopmans KP, et al. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med. 2005;46(7):1240–3.
    1. Kvols LK, et al. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313(19):1229–30. doi: 10.1056/NEJM198511073131916.
    1. Harris AL, Smith IE. Tryptophan in the treatment of carcinoid crisis. Cancer Chemother Pharmacol. 1983;10(2):137–9. doi: 10.1007/BF00446228.
    1. Guo LJ, Tang CW. Somatostatin analogues do not prevent Carcinoid crisis. Asian Pacific J Cancer Prev. 2014;15(16):6679–83. doi: 10.7314/APJCP.2014.15.16.6679.
    1. Weingarten TN, et al. Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg. 2007;105(5):1192–9. doi: 10.1213/01.ane.0000284704.57806.0b. table of contents.
    1. Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. Arch Dermatol. 1972;105(4):574–7. doi: 10.1001/archderm.1972.01620070046016.
    1. Swain CP, Tavill AS, Neale G. Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia. Gastroenterology. 1976;71(3):484–9.
    1. Shah GM, et al. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005;100(10):2307–14. doi: 10.1111/j.1572-0241.2005.00268.x.
    1. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. 2004;43(1):1–5.
    1. Bouma G, et al. Niacin (Vitamin B3) supplementation in serotonin producing neuroendocrine tumor patients. Neuroendocrinology. 2015.
    1. Chambers AJ, et al. Impairment of cognitive function reported by patients suffering from carcinoid syndrome. World J Surg. 2010;34(6):1356–60. doi: 10.1007/s00268-010-0404-9.
    1. Pasieka JL, et al. Cognitive impairment associated with carcinoid syndrome. Ann Surg. 2014;259(2):355–9. doi: 10.1097/SLA.0b013e318288ff6d.
    1. Russo S, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med. 66(3):422–5.
    1. Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med. 1967;277(21):1103–8. doi: 10.1056/NEJM196711232772101.
    1. Kulke MH, et al. Telotristat Etiprate Shows Benefit in Treating Patients with Carcinoid Syndrome that is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial. NANETS Symp. 2015. Abstract C.
    1. Berry EM, Maunder C, Wilson M. Carcinoid myopathy and treatment with cyproheptadine (Periactin) Gut. 1974;15(1):34–8. doi: 10.1136/gut.15.1.34.
    1. Walsh JS, et al. Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. J Clin Endocrinol Metab. 2013;98(7):2902–7. doi: 10.1210/jc.2012-4174.
    1. Donowitz M, Binder HJ. Jejunal fluid and electrolyte secretion in carcinoid syndrome. Am J Dig Dis. 1975;20(12):1115–22. doi: 10.1007/BF01070754.
    1. Gelhorn HL, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759–68. doi: 10.1016/j.clinthera.2016.03.002.
    1. Borman RA, Burleigh DE. Heterogeneity of 5-HT receptors mediating secretion in the human intestine. Ann N Y Acad Sci. 1997;812:224–5. doi: 10.1111/j.1749-6632.1997.tb48183.x.
    1. Jackson LN, et al. Development and characterization of a novel in vivo model of carcinoid syndrome. Clin Cancer Res. 2009;15(8):2747–55. doi: 10.1158/1078-0432.CCR-08-2346.
    1. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):14–21. doi: 10.1097/MED.0b013e32835bc703.
    1. Makridis C, et al. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg. 1996;20(7):900–6. doi: 10.1007/s002689900137. discussion 907.
    1. Carter CA, et al. Flushing out carcinoid syndrome: beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor. Case Rep Oncol. 2015;8(3):461–5. doi: 10.1159/000441775.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться